Mark Cuban Cost Plus Drug Company, PBC
Mark Cuban Cost Plus Drug Company, PBC, launched in 2018, operates as a public-benefit corporation in the healthcare sector, focusing on providing safe, high-quality medications at transparent and low prices.
Company Name and Former Names
The company is currently known as Mark Cuban Cost Plus Drug Company, PBC. It was formerly known as Osh's Not-for-Profit Pharmaceuticals and Osh's Affordable Pharmaceuticals.
Industry and Sub-Industry
Mark Cuban Cost Plus Drug Company, PBC operates within the Healthcare industry, specifically focusing on Consumer Health and Wellness.
Public-Benefit Corporation Mission
As a public-benefit corporation, Mark Cuban Cost Plus Drug Company, PBC prioritizes a social mission of improving public health. The company's operations focus on offering safe medicines at the lowest possible prices and providing complete transparency on the cost of drugs.
Operational Model
The company bases its prices on the cost to get each medication from the manufacturer to the customer, eliminating pharmacy middlemen. A 15% markup is added to support operations and provide quality service. Shipping is charged once per order, not per medication.
Insurance Partnerships and Fulfillment Partners
Mark Cuban Cost Plus Drug Company, PBC accepts prescription insurance for AffirmedRx, Archimedes, Capital Blue Cross, Drexi, MedOne, Oread Rx, PCA Rx, Rightway, RxPreferred, SGRX, SmithRx, VIVIO, and other select prescription plans. The company works with HealthDyne and Truepill as trusted fulfillment partners, with licensed pharmacists ensuring safe dispensing and shipping of medications.
Pharmaceutical Facility in Dallas, Texas
The company is building a state-of-the-art pharmaceutical facility in Dallas, Texas. This facility will focus on producing high-quality medicines at the lowest possible prices. This initiative aligns with the company's mission to make low-cost versions of high-cost generic drugs.
Company Launch and Y Combinator Batch
Mark Cuban Cost Plus Drug Company, PBC was launched in 2018 and participated in Y Combinator's S18 batch.